PSI-6130

PSI-6130
Clinical data
ATC code	none;
Identifiers
CAS Number	817204-33-4;
CompTox Dashboard (EPA)	DTXSID10231287 ;
Chemical and physical data
Formula	C36H53N7O6
Molar mass	259.23 g/mol g·mol−1

PSI-6130 is an experimental treatment for hepatitis C. It is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark ^[1]；specifically, telaprevir inhibits the hepatitis C virus NS3.4A serine protease.^[2]

PSI-6130 is currently being developed by Hoffmann–La Roche as a diisobutyrl ester prodrug, R7128.^[3]

References

^ Clark, J.; et al. (2005). "Design, synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'C-methylcytidine, a potent inhibitor of hepatitis C virus replication". Journal of Medicinal Chemistry. 48 (17): 5504. doi:10.1358/dof.2007.032.09.1138229. {{cite journal}}: Explicit use of et al. in: |author= (help)
^ Lin C, Kwong AD, Perni RB (2006). "Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease". Infect Disord Drug Targets. 6 (1): 3–16. PMID 16787300. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
^ McHutchison JG, Manns MP, Muir AJ; et al. (2010). "Telaprevir for previously treated chronic HCV infection". N. Engl. J. Med. 362 (14): 1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[1] Clark, J.; et al. (2005). "Design, synthesis and antiviral activity of 2'-deoxy-2'-fluoro-2'C-methylcytidine, a potent inhibitor of hepatitis C virus replication". Journal of Medicinal Chemistry. 48 (17): 5504. doi:10.1358/dof.2007.032.09.1138229. {{cite journal}}: Explicit use of et al. in: |author= (help)

[pmid16787300-2] Lin C, Kwong AD, Perni RB (2006). "Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease". Infect Disord Drug Targets. 6 (1): 3–16. PMID 16787300. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[3] McHutchison JG, Manns MP, Muir AJ; et al. (2010). "Telaprevir for previously treated chronic HCV infection". N. Engl. J. Med. 362 (14): 1292–303. doi:10.1056/NEJMoa0908014. PMID 20375406. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]